Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions

Br J Haematol. 2007 Sep;138(5):587-93. doi: 10.1111/j.1365-2141.2007.06695.x. Epub 2007 Jul 4.

Abstract

Magnetic resonance imaging (MRI) was used to quantify myocardial iron loading by T2* in 11 transfusion-dependent good prognostic myelodysplastic syndrome (MDS) patients. Myocardial T2*, left ventricular function and hepatic T2* were measured simultaneously. Patients had been on transfusion therapy for 13-123 months and had serum ferritin levels of 1109-6148 microg/l at the time of study. Five patients had not commenced iron chelation and had been transfused with a median of 63 red cell units and had a median serum ferritin level of 1490 microg/l. Six patients were on iron chelation and had been transfused with a median of 112 red cell units and had a median serum ferritin level of 4809 mug/l. Hepatic iron overload was mild in two, moderate in seven and severe in two patients. The median liver iron concentration was 5.9 mg/g dry weight in chelated patients and 9.5 mg/g in non-chelated patients (P = 0.17; not significant). Myocardial T2* indicated absent iron loading in 10/11 patients (91%; 95% confidence interval 62-98%) and borderline-normal in one patient. Left ventricular function was normal in all patients. No correlation was observed between increasing serum ferritin levels, hepatic iron overload and myocardial T2*. A long latent period relative to hepatic iron loading appears to predate the development of myocardial iron loading in transfusion-dependent MDS patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Ferritins / blood
  • Follow-Up Studies
  • Humans
  • Iron / metabolism
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / diagnosis*
  • Iron Overload / drug therapy
  • Iron Overload / etiology
  • Iron Overload / metabolism
  • Liver / metabolism
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / metabolism
  • Myelodysplastic Syndromes / therapy*
  • Myocardium / metabolism*
  • Prognosis
  • Prospective Studies
  • Transfusion Reaction*

Substances

  • Iron Chelating Agents
  • Ferritins
  • Iron